Clinical programmes designed to global standards.
Our clinical studies are designed with reference to EMA guidelines and conducted to ICH-GCP. Our insulin aspart programme has been reviewed by the European Medicines Agency through Scientific Advice. The studies were conducted at multiple centres in India.
Studies by product.
Insulin aspart
A euglycaemic clamp study in healthy volunteers showed pharmacokinetic and pharmacodynamic equivalence to the reference medicine (Clin Pharmacol Drug Dev, 2025).
A randomised, open-label, multicentre study against NovoRapid® in adults with type 2 diabetes assessed efficacy, safety and immune response (Res Pharm Sci, 2024; J Endocrinol Invest, 2023).
A multicentre, open-label, single-arm, Phase IV study to assess the safety and efficacy of InsuQuick™ (insulin aspart) in adult patients with type 2 diabetes mellitus.
Insulin aspart mix
A euglycaemic clamp study in healthy volunteers showed pharmacokinetic and pharmacodynamic equivalence to the reference medicine (NovoMix® 30 of Novo Nordisk).
A randomised, open-label, multicentre study against NovoMix® 30 in people with diabetes, completed. Approved in India in September 2025.
Insulin glargine
A euglycaemic clamp study in healthy volunteers showed pharmacokinetic and pharmacodynamic equivalence to the reference medicine (Lantus®, insulin glargine 100 IU/mL, of Sanofi-Aventis).
A randomised, open-label, multicentre study against Lantus®, completed. The final clinical study report has been submitted to the Indian regulator.
A clear, staged route to global markets.
All three of our lead products have been developed for approval in regulated markets. Insulin aspart and insulin aspart mix are approved in India. Our first European filing, for insulin aspart, is planned for 2027.
| Product | India | Europe | Other markets |
|---|---|---|---|
| Insulin aspart | Approved; marketed since October 2023 | Filing planned 2027 | Registrations with partners in progress |
| Insulin aspart mix | Approved September 2025 | Planned | Registrations with partners in progress |
| Insulin glargine | Phase III completed; approved by SEC | Planned | Registrations with partners in progress |
European approval also supports registration in many other countries that refer to European assessments.
Safety is watched every day, not once.
Patient safety is central to our work. We monitor the safety of our medicines for as long as they are in use. We collect, assess and report adverse events from healthcare professionals, patients and partners, in line with regulatory requirements.
We review safety data continuously, including periodic safety reports and signal detection, so that any new risk is found early and acted upon. Since launch, we have submitted periodic safety update reports to the Indian regulator every six months.
Tell us about a side effect.
To report a side effect of any BioGenomics medicine, contact our pharmacovigilance team:
Email: wecare@biogenomics.co.in
Toll-free: 1800 202 3031
If a side effect is serious, contact your doctor or go to the nearest hospital straight away.